Literature DB >> 11421355

MUC1 in carcinoma-host interactions.

K Denda-Nagai1, T Irimura.   

Abstract

Many carcinoma-associated markers are glycoconjugates whose expression undergoes temporal or spatial regulation. Mucin-1 (MUC1), discovered through monoclonal antibody technology, is a well-documented example of such a molecule and influences numerous pathophysiological behaviors, such as the invasion and metastasis of carcinoma cells. Levels of MUC1 expression in carcinomas correlate with the clinical stage of the cancer and inversely correlate with the survival prospects of patients. The MUC1 immune response is known to provide a protective host defense mechanism against cancer. The multiple functions of MUC1 in carcinoma-host interactions are believed to be dependent on the polymorphic nature of MUC1, particularly its glycosylation status.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11421355     DOI: 10.1023/a:1011039013134

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   3.009


  108 in total

1.  Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

Authors:  G A Pietersz; W Li; C Osinski; V Apostolopoulos; I F McKenzie
Journal:  Vaccine       Date:  2000-04-03       Impact factor: 3.641

2.  Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function.

Authors:  A Baruch; M Hartmann; S Zrihan-Licht; S Greenstein; M Burstein; I Keydar; M Weiss; N Smorodinsky; D H Wreschner
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

3.  Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.

Authors:  S von Mensdorff-Pouilly; E Petrakou; P Kenemans; K van Uffelen; A A Verstraeten; F G Snijdewint; G J van Kamp; D J Schol; C A Reis; M R Price; P O Livingston; J Hilgers
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

4.  Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.

Authors:  Y Masaki; M Oka; Y Ogura; T Ueno; K Nishihara; A Tangoku; M Takahashi; M Yamamoto; T Irimura
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

5.  Purification and characterization of the MUC1 mucin-type glycoprotein, epitectin, from human urine: structures of the major oligosaccharide alditols.

Authors:  V P Bhavanandan; Q Zhu; K Yamakami; N A Dilulio; S Nair; C Capon; J Lemoine; B Fournet
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

6.  MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral.

Authors:  V Apostolopoulos; C Osinski; I F McKenzie
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

7.  Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.

Authors:  V Apostolopoulos; P X Xing; I F McKenzie
Journal:  Cancer Res       Date:  1994-10-01       Impact factor: 12.701

8.  Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules.

Authors:  S Zrihan-Licht; A Baruch; O Elroy-Stein; I Keydar; D H Wreschner
Journal:  FEBS Lett       Date:  1994-12-12       Impact factor: 4.124

9.  Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody.

Authors:  D Baeckström; O Nilsson; M R Price; L Lindholm; G C Hansson
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

10.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.

Authors:  S Nakamori; D M Ota; K R Cleary; K Shirotani; T Irimura
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

View more
  10 in total

1.  Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry.

Authors:  Mayuko Takagawa; Naoki Muguruma; Kaori Oguri; Yoshitaka Imoto; Koichi Okamoto; Kunio Ii; Susumu Ito
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Detection of circulating tumor cells in cancers of biliary origin.

Authors:  Omar Al Ustwani; Dan Iancu; Rabi Yacoub; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2012-06

3.  Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens by dendritic cells.

Authors:  Kaori Denda-Nagai; Satoshi Aida; Kengo Saba; Kiwamu Suzuki; Saya Moriyama; Sarawut Oo-Puthinan; Makoto Tsuiji; Akiko Morikawa; Yosuke Kumamoto; Daisuke Sugiura; Akihiko Kudo; Yoshihiro Akimoto; Hayato Kawakami; Nicolai V Bovin; Tatsuro Irimura
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

4.  The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo.

Authors:  Masaki Imai; Hee-Young Hwang; James S Norris; Stephen Tomlinson
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

5.  Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.

Authors:  M V Croce; M Isla-Larrain; R Tur; M E Rabassa; A Segal-Eiras
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo.

Authors:  Daisuke Sugiura; Kaori Denda-Nagai; Mitsuyo Takashima; Ryuichi Murakami; Shigenori Nagai; Kazuyoshi Takeda; Tatsuro Irimura
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

7.  Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model.

Authors:  Hidenori Ozaki; Hideki Matsuzaki; Hidenobu Ando; Hiroyuki Kaji; Hayao Nakanishi; Yuzuru Ikehara; Hisashi Narimatsu
Journal:  Clin Exp Metastasis       Date:  2012-01-08       Impact factor: 5.150

Review 8.  EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.

Authors:  M A Chaudry; K Sales; P Ruf; H Lindhofer; M C Winslet
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

9.  Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Authors:  Mark D Pegram; Virginia F Borges; Nuhad Ibrahim; Jyotsna Fuloria; Charles Shapiro; Susan Perez; Karen Wang; Franziska Schaedli Stark; Nigel Courtenay Luck
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  Natural and Induced Humoral Responses to MUC1.

Authors:  Silvia Von Mensdorff-Pouilly; Maria Moreno; René H M Verheijen
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.